VBWG

All

Will Incretin Therapy Change Obesity and Prediabetes Management?

Sanjay Rajagopalan, MD, FACC
Case Western Reserve University School of Medicine
Cleveland, OH

Time to Start Prescribing Diabetes Agents: A Cardiologists Call to Action

David H. Fitchett, MD, FACC
University of Toronto
Toronto, ON, Canada

Regression of Coronary Atherosclerosis: Current Evidence and Future Perspectives

Stephen J. Nicholls, MBBS, PhD, FACC
University of Adelaide
Adelaide, Australia

Therapeutic Targeting of LP(a), APOC-III, and ATP-Citrate Lyase for Cardiovascular Disease

Sotirios Tsimikas, MD, FACC
UC San Diego School of Medicine
La Joila, CA

Aspirin: How Important is Platelet Resistance?

Jawahar L. Mehta, MD, PhD, FACC
University of Arkansas for Medical Sciences
Little Rock, AR

Cardiorenal Disorders: Recent Advances, Novel Therapies

Peter A. McCullough, MD, MPH
Baylor Heart and Vascular Institute
Dallas, TX

Using TAVR in Lower and Lower Risk Patients.

Ron Waksman, MD
Washington Hospital Center
Washington, DC

Lipids 2016: Update on the Metamorphosis Occurring in Lipid Therapy Today.

Robert P. Giugliano, MD
TIMI Study Group
Boston, MA  

Benefits and Limitations of Antiplatelet Therapy. How Can We Advance the Field?

Paul A. Gurbel, MD
Johns Hopkins University School of Medicine
Baltimore, MD 

Current and Future Perspectives in the Treatment of Pulmonary Hypertension.

Paul R. Forfia, MD
Temple University School of Medicine
Philadelphia, PA

What Have We Learned From Recent Trials for PAD and Where Are We Headed?

William R. Hiatt, MD
University of Colorado School of Medicine
Denver, CO 

Recent Advances in Diagnostic Imaging for Peripheral Arterial Disease

Joao A. C. Lima, MD, FACC
Johns Hopkins School of Medicine
Baltimore, MD

Nanotherapeutic Solutions for Peripheral Arterial Disease

John P. Cooke, MD, PhD, FACC
Houston Methodist Research Institute
Houston, TX

HIV, Inflammation and Cardiovascular Disease

Priscilla Y. Hsue, MD, FACC
UCSF School of Medicine
San Francisco, CA

Transcatheter Mitral Valve Replacement: Hope or Hype?

Howard C. Herrmann, MD, FACC
University of Pennsylvania
Philadelphia, PA

Utilizing Novel Therapies in Atherosclerosis: From Antibodies to Nanotechnology

Erik Stroes MD, PhD
Academic Medical Center
Amsterdam, Netherlands

Modifying CVD Risk by Managing Hyperglycemia: The Dawn of a New Era?

Jorge Plutzky, MD
Brigham and Women's Hospital
Boston, MA

Advancing the Cardiovascular Care of Our Cancer Patients: Where Are We Now?

Javid Moslehi, MD
Vanderbilt University
School of Medicine
Nashville, TN

Tailoring Oral Anticoagulation in Elderly Patients with Atrial Fibrilation

Christopher Granger, MD
Duke University
School of Medicine
Durham, NC

How We Should Manage HTN in Adults: The Importance of Diastolic Blood Pressure with Lower Systolic Targets

Deepak Bhatt, MD, MPH
Brigham and Women's Hospital 
Heart and Vascular Center
Boston, MA

Cardiac Care for Older Adults: Why is the Demography Important?

Nanette Wenger, MD
Emory University
School of Medicine
Atlanta, GA

Living with Heart Disease in Old Age: Shifting Priorites of Care for Older Cardiac Patients

Daniel Forman, MD
Professor, Department of Medicine
University of Pittsburgh

HFpEF in Older Adults: TTR Amyloid, Under Diagnosed and Treatable?

Mathew Maurer, MD
Columbia University
Medical Center
New York, NY

CKD: An Independent CV Risk Factor in the Elderly

George Bakris, MD
University of Chicago Medicine
Chicago, IL

No Automatic Prescribing in Those > 75 Years. Why Guideline Directed Clinician-Patient-Risk Discussion Crucial

Neil Stone, MD
Northwestern University
Feinburg School of Medicine
Chicago, IL

Integrating Big Data with Evidence Generation for Precision Medicine: Implications for Cardiovascular Disease.

Elliott M. Antman, MD, MACC
Immediate Past President AHA
Harvard Medical School
Boston, MA

Treating HTN Today: Insights from SPRINT and the New Clinical Practice Guidelines for Patients with CAD.

Clive Rosendorff, MD, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Cardiovascular Outcomes with Medicines to Control Glycemia: Highlights from Recently Completed Trials.

Darren K. McGuire, MD, MHSc
UT Southwestern Medical Center
Dallas, TX

Where Are We With Systolic Heart Failure?

Ileana Pina, MD, MPH
Montefiore Medical Center
Bronx, NY

Are We Back to Lower is Better: Time to Revise the 2014 Guidelines?

Stephen D. Wiviott,  MD
Brigham and Women’s Hospital
Boston, MA 

New Directions in Antiplatelet Therapy

David A. Morrow, MD, MPH
Brigham and Women’s Hospital
Boston, MA

The Emerging Role of Gut Microbiota in CVD and Thrombosis.

Stanley L. Hazen, MD, PhD
Cleveland Clinic
Cleveland, OH

Reducing CV Risk with Glucose Lowering Drugs: Recent Breakthroughs.

Silvio E. Inzucchi, MD
Yale University School of Medicine
New Haven, CT

Eliminating Barriers That Prevent Optimal Stroke Prevention in Patients with Afib.

Christian T. Ruff, MD
Brigham and Women’s Hospital
Boston, MA

The Next Frontier in Heart Failure: Where Are We Going?

Scott D. Solomon, MD
Brigham and Women’s Hospital
Boston, MA 

Cardiorenal Disorders: Recent Advances, Novel Therapies.

Peter A. McCullough, MD, MPH
Baylor Heart and Vascular Institute
Dallas, TX

Impacting Lipid Disorders Through Personalized Healthcare: What the Future Holds.

Daniel J. Rader, MD
University of Pennsylvania School of Medicine
Philadelphia, PA

Personalized Medicine in Patients with Coronary Artery Disease.

Jean-Claude Tardif, , MD
Montreal Heart Institute
Montreal, QC, Canada

The Future of Healthcare and the Role of the National Academy of Medicine.

Victor J. Dzau, MD
National Academy of Medicine
Washington, DC

Molecular Imaging in the Era of Personalized Medicine.

Mehran Sadeghi, MD
Yale University School of Medicine
New Haven, CT

PREVIOUS CONFERENCES

 

VBWG Meeting at ACC
March 16, 2017
Washington, DC
AGENDA - VIEW PRESENTATIONS


VBWG Global Chapter Meeting at AHA
November 12, 2016
New Orleans, LA
AGENDA - VIEW PRESENTATIONS


VBWG US Chapter Meeting at ACC
April 1, 2016
Chicago, IL
AGENDA - VIEW PRESENTATIONS


VBWG Global Chapter Meeting
November 7, 2015
Orlando, FL
AGENDA - VIEW PRESENTATIONS

VBWG US Chapter Meeting
March 13, 2015
San Diego, CA
AGENDA - VIEW PRESENTATIONS


VBWG Global Chapter Meeting
November 15, 2014
Chicago, IL
AGENDA - VIEW PRESENTATIONS

VBWG US Chapter Meeting
March 28, 2014
Washington, DC
AGENDA - VIEW PRESENTATIONS

VBWG Global Chapter Meeting
November 16, 2013
Dallas, TX
AGENDA - VIEW PRESENTATIONS

 

NOACS for Valve Disease?

A. John Camm, MD
St. George’s University Hospital
London, UK

New Oral Interventions for Heart Failure.

Javed Butler,  MD, MPH
Stony Brooke University School of Medicine
Stony Brook, NY

Beyond Statins: The Coming Revolution in Lipid Therapy

Christie Ballantyne, MD
Baylor College of Medicine
Houston, TX

Cell Therapy: Where Are We Today and Where Are We Headed?

Eduardo Marban, MD, PhD
Cedars-Sinai Hospital
Los Angeles, CA

Bariatric Surgery for Obesity and Cardiometabolic Conditions: Time to Embrace?

Michael E. Farkouh, MD, MSc
University of Toronto
Toronto, ON, Canada 

Where Are We With Diastolic Heart Failure?

Christopher O’Connor, MD
Duke University Medical Center
Durham, NC

The Rapidly Evolving Field of TAVR

John G. Webb, MD
St. Paul’s Hospital
Vancouver, BC, Canada

Percutaneous MVR After Everest II: What the Future Holds

Ted E. Feldman, MD
NorthShore University HealthSystem
Evanston, IL

Heart Disease in Women: Have We Made Progress?

C. Noel Bairey Merz, MD
Cedars-Sinai Hospital

Managing Type 2 Diabetes: New and Future Developments in Treatment

Silvio E. Inzucchi, MD
Yale School of Medicine

New Developments in the Treatment of Heart Failure

John J. McMurray, MD
University of Glasgow

New Frontiers in Cardiac Biomarkers

Alan S. Maisel, MD
University of California San Diego

PCSK9 and Atherosclerosis: Will We Target Risk with Monoclonal Antibodies or Only LDL-C?

Michael J. Koren, MD
Jacksonville Ctr. For Clinical Research

HDL Dysfunction in Coronary Artery Disease: An Enigma or Dead?

Stephen J. Nicholls, MBBS, PhD
South Australian Health and Medical Research Institute

Emerging Therapies on the Horizon for Hypertriglyceridemia

Ira Goldberg, MD
NYU Langone Medical Center

Is Left Atrial Occlusion Really an Alternative to Lifelong Anticoagulation?

David R Holmes Jr. MD, Mayo Clinic, Rochester, MN

Turning White Fat to Brown: Foe to Friend or Not?

Jorge Plutzky MD, Brigham and Women's Hospital

Serelaxin: Breakthrough Therapy or Also-ran?

John R Teerlink MD, UCSF School of Medicine

A Novel Approach to Preventing Aortic Stenosis

Jean-Claude Tardif MD, Montreal Heart Institute

Future Pharmacological Options for Heart Failure

Christopher O'Connor MD, Duke University Medical Center

The VBWG Twentieth Anniversary

Dr Carl J. Pepine reports on the achievements of the Vascular Biology Working Group at the National Faculty Meeting, Washington, DC. The Vascular Biology Working Group celebrated its twentieth anniversary at its meeting just preceding the American College of Cardiology Annual Scientific Sessions (ACC14) in Washington, DC, on 28 March 2014

PCSK9 Inhibitors and the Unmet Need for LDL-C Reduction

Evan A Stein MD, PhD, University of Cincinnati

HRT: Help or Harm to the Heart?

Eliot A Brinton MD, University of Utah School of Medicine

High LP(a): Causal Role in Calcific Stenosis and Other CV Diseases

Sotirios Tsimikas MD, UC San Diego School of Medicine

Direct Inhibition of Inflammation: CANTOS, CIRT, and Beyond

Paul M Ridker MD, Brigham and Women's Hospital

New Approaches to Modifying Risk by Improved Glycemic Management

Deepak L Bhatt MD, MPH, Harvard Medical School

Aging, Longevity Genes and Atherosclerosis: The Key to Living to 100?

Thomas Luscher MD, University Hospital, Zurich, Switzerland

Novel Therapies for Pulmonary Hypertension: Where Are We Going?

Lewis J Rubin MD, UC San Diego School of Medicine

Oral Anticoagulants in Development

Robert P Giugliano MD, Brigham and Women's Hospital

Core Curriculum

Progress and Promise in RAAS Blockade

View/Download individual slides (82 Slides)

Core Curriculum

Leading the Way in Cardiovascular Regenerative Medicine

View/Download individual slides (54 Slides)

Core Curriculum

Vascular Dysfunction: Sequelae of Acute Hypertension

View/Download individual slides (84 Slides)

Managing CV Risk in Diabetes: Setting More Aggressive Goals to Meet a Growing Crisis

The evolving diabetes epidemic is raising concern over the adverse long-term effect on cardiovascular (CV) disease.

Core Curriculum

Myocardial Ischemia Redefined: Optimal Care in CAD

View/Download individual slides (90 Slides)

Core Curriculum

Hyperglycemia and Acute Coronary Syndromes

View/Download individual slides (84 Slides)

Core Curriculum

Contemporary Management of Cardiometabolic Risk

View/Download individual slides (105 Slides)

A Diabetes Outcome Progression Trial

ADOPT

This resource is not available online, you may order a copy of this data alert if it is in stock.

Core Curriculum

Advancing Our Understanding of RAAS Modulation in High-Risk Patients

View/Download individual slides (67 Slides)

Drug-Eluting Stents: FDA Advisory Panel 2006

FDA Advisory Panel Highlights December 7 FDA Advisory Panel Highlights December 8 FDA Advisory Panel Meeting Agenda December 7 FDA Advisory Panel Meeting Agenda December 8 FDA Advisory Panel Meeting Roster

ADOPT: A Diabetes Outcome Progression Trial

View/Download individual slides (15 Slides)

RIO-Diabetes trial: Rimonabant In Obesity

View/Download individual slides (13 Slides)

Core Curriculum

Targeting Insulin Resistance for Vascular Protection

View/Download individual slides (120 Slides)

ERICA: Efficacy of Ranolazine In Chronic Angina

View/Download individual slides (11 Slides)

Rimonabant: Managing Multiple Cardiometabolic Risk Factors

View/Download individual slides (12 Slides)

Core Curriculum

Contemporary Management of Myocardial Ischemia

View/Download individual slides (119 Slides)

ExTRACT-TIMI 25 study

Results from ExTRACT-TIMI 25: The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction Study 25

ASCOT: New Insights on Aggressive Risk Factor Intervention to Prevent Major CV Events In Hypertensive Patients

Cardiovascular (CV) disease remains the leading cause of death in the United States, claiming more lives each year than the next four leading causes of death combined.

TROPHY trial

TROPHY results: Tr ial O f Preventing Hy pertension

ASTEROID trial

Results from ASTEROID: A Study to evaluate the Effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden

OASIS-6 trial

OASIS-6 trial results: The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial

OASIS-5 trial

OASIS-5 results: The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial

Vascular Biology in Clinical Practice TM Vol. 7, No. 2

New Frontiers in CVD Risk Management Supporting Early Aggressive Therapy

This monograph, New Frontiers in CVD Risk Management Supporting Early Aggressive Therapy , is offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

HOPE-2 trial

HOPE-2 results: No CV benefit from homocysteine lowering with folic acid plus B vitamins in high-risk patients

Core Curriculum

Antiplatelet Interventions in ACS

View/Download individual slides (104 Slides)

New ACC/AHA Guidelines: Expanding the Role of Angiotensin Receptor Blockade in Heart Failure with LV Dysfunction

The 2005 ACC/AHA updated guidelines for the treatment of chronic HF and LV dysfunction in adults include an expanded role for ARBs as alternative therapy to ACEIs in selected patients and as added neurohormonal therapy in patients with persistent symptoms who are receiving optimal treatment.

CAFE, an ASCOT substudy

View/Download individual slides (7 Slides)

Core Curriculum

New Frontiers in CVD Risk Management: Optimizing Outcomes in Patients with Multiple Cardiovascular Risks

View/Download individual slides (129 Slides)

PROactive: The first prospective clinical outcomes trial of PPAR g agonists

Compared with the general population, persons with diabetes have a twofold greater absolute risk of cardiovascular (CV) disease.

Results from CRUSADE: Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines

CRUSADE investigated the association between dosing levels of antithrombotic agents and bleeding, in-hospital mortality, and length of stay in patients with NSTE ACS.

Vascular Biology in Clinical Practice © Vol. 7, No. 1

ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection

This monograph, ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection , which is being offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

Core Curriculum

Insulin Resistance and Cardiovascular Disease: New Perspectives From Vascular Biology

View/Download individual slides (94 Slides)

HOPE-TOO: Extended use of ACEI reduces CV risk and new diabetes, independent of baseline risk

Results from large clinical trials provide evidence that angiotensin-converting enzyme inhibitors (ACEIs) are effective in the treatment of cardiovascular (CV) disease.

Results from ASCOT-BPLA: A nglo- S candinavian C ardiac O utcomes T rial-Blood Pressure Lowering Arm

ASCOT-BPLA compared two combination antihypertensive regimens in 19,257 hypertensive patients with 3 or more other CV risk factors.

Core Curriculum

The Renin-Angiotensin-Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction

View/Download individual slides (93 Slides)

HOPE-TOO: Results of the HOPE Study Extension

View/Download individual slides (12 Slides)

Core Curriculum

RAAS Modulation: Novel Strategies for Reducing Cardiovascular Risk

View/Download individual slides (82 Slides)

Core Curriculum

Improving Outcomes in Heart Failure: New Insights From Vascular Biology

View/Download individual slides (53 Slides)

TNT: New data on intensive lipid lowering in stable CAD patients

View/Download individual slides (16 Slides)

New data on optimal BP lowering in CAD patients: CAMELOT

The results of the Comparison of Amlodipine vs Enalapril to Limit Occurrence of Thrombosis (CAMELOT) study have recently been published.

Vascular Biology in Clinical Practice © Vol. 6, No. 3

A HOPE FOR PEACE? Update on the role of ACE inhibition in CAD patients

This monograph, A HOPE for PEACE? Update on the role of ACE inhibition in CAD patients , is offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section IV - Update: RAAS manipulation and cardiovascular risk--Hope for Peace?

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Vascular Biology in Clinical Practice © Vol. 6, No. 2

High-dose statins and early benefit in ACS: Role of inflammation

This monograph, High-dose statins and early benefit in ACS: Role of inflammation , is offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

The INTERHEART Study: New data on global risk

Cardiovascular disease (CVD) is estimated to be the leading cause of mortality and morbidity worldwide.

Expanding opportunities for secondary prevention of stroke

Between 1979 and 2001, the number of patients discharged from the hospital with a primary diagnosis of stroke increased by 25%.

The new mandate for multiple risk reduction

Reducing the morbidity and mortality associated with cardiovascular (CV) disease is becoming as much a public health challenge as it is a research challenge.

Vascular Biology in Clinical Practice © Vol. 6, No. 1

How low should LDL-C level be? New data, new direction

This monograph, How low should LDL-C level be? New data, new direction, offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section V: Multiple risk and CV disease prevention

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Preventing stroke in AF: New data on role of antithrombotic therapy

All forms of atrial fibrillation (AF), whether permanent, persistent, or paroxysmal, are associated with an increased risk of stroke and antithrombotic therapy is recommended for almost all AF patients.

Role of lipid lowering for prevention of cardiovascular events in type 2 diabetes

Cardiovascular (CV) disease is the primary complication and cause of death in people with type 2 diabetes mellitus, 1 accounting for nearly two thirds of deaths.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section IV: RAAS manipulation and cardiovascular risk

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section III: Heart failure: The new vascular biology imperative to blunt progression

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section II: Blunting the atherosclerotic process: The case for aggressive lipid management

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section I: Atrial fibrillation, anticoagulation, and stroke prevention

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Blunting the atherosclerotic process in patients with coronary artery disease

Statin therapy lowers serum levels of atherogenic lipoproteins and reduces cardiovascular (CV) morbidity and mortality in a wide range of patients in clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section V: Atrial fibrillation, anticoagulation, and stroke prevention

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Vascular Biology in Clinical Practice © Vol. 5, No. 3

Atrial fibrillation and thromboembolism: Implications for stroke prevention

This monograph, Atrial fibrillation and thromboembolism: Implications for stroke prevention , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

Statins and safety: Overview for patient care

Hypercholesterolemia is one of the major modifiable risk factors for coronary heart disease.

The CHARM program: Enhancement of RAAS manipulation in heart failure

Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors 1 and ß-blockers 2-4 in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF).

Vascular Biology in Clinical Practice © Vol. 5, No. 2

Managing lipids in patients with diabetes: New evidence from vascular biology and clinical trials

This monograph, Managing lipids in patients with diabetes: New evidence from vascular biology and clinical trials , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

COMET: Results and implications for the treatment of heart failure

Over the course of 25 years, the use of ß-blocking agents to treat heart failure has evolved from a contraindication to an established treatment for mild-to-moderate disease.

Vascular Biology in Clinical Practice © Vol. 5, No. 1

New strategies for global risk reduction: Focus on lipids and blood pressure

This monograph, New strategies for global risk reduction: Focus on lipids and blood pressure, is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

ASCOT-LLA: Extending benefits of statins to hypertensive patients

Hypertension and hypercholesterolemia frequently coexist and the interaction of these important risk factors increases cardiovascular risk considerably.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section III: Neurohormonal strategies in the failing heart

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section II: Lipid management

The VBWG Core Curriculum 2003 slide lecture compendium, Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section I: RAAS manipulation

The VBWG Core Curriculum 2003 slide lecture compendium, Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Vascular Biology in Clinical Practice © Vol. 4, No. 6

Prevention of stroke and cognitive dysfunction

This monograph, Prevention of stroke and cognitive dysfunction , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

Cardiovascular considerations in treating erectile dysfunction

Impact of vascular biology in treatment of cardiovascular disease

This slide presentation covers basic science and clinical advances in treatment of erectile dysfunction, with emphasis on the cardiovascular patient.

Vascular Biology in Clinical Practice © Vol. 4, No. 5

The potential role of beta-blockade in blunting the progression of atherosclerosis

This monograph, The potential role of beta-blockade in blunting the progression of atherosclerosis , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

Decrease in PAI-1 antigen is greater with ACE inhibition

Plasminogen activator inhibitor-1 (PAI-1) is a known risk factor for cardiovascular (CV) disease and myocardial infarction (MI).

Vascular Biology in Clinical Practice © Vol. 4, No. 4

Anticoagulant therapy in the PCI patient

This monograph, Anticoagulant therapy in the PCI patient , is intended to explore the role of anticoagulant therapy in patients scheduled for percutaneous coronary intervention, particularly as it is evolving in regard to other components of antithrombotic therapy (i.

RITA 3: Benefit of early invasive strategy in moderate-risk unstable angina patients

Final results of RITA 3 (Randomized Intervention Trial of unstable Angina) confirm that an interventional strategy results in a statistically significant reduction in the combined outcome of death, nonfatal myocardial infarction (MI), or refractory angina.

Vascular Biology in Clinical Practice © Vol. 4, No. 3

Peri-interventional care: Rationale for ACE manipulation

This monograph, Peri-interventional care: Rationale for ACE manipulation , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

New data on aggressive lipid-lowering management

The results of several recent trials affirm the importance of intensive lipid lowering in at-risk patients.

MERIT-HF: Impact of ß-blocker dose on outcomes in patients with heart failure

In a post hoc subgroup analysis, the MERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure) researchers examined the relation of ß-blocker dose to clinical outcomes.

HOPE: Effect of long-term therapy with ACE inhibition in high-risk women

Cardiovascular (CV) disease is currently the leading cause of death and the main hospital diagnosis in postmenopausal women.

Vascular Biology in Clinical Practice © Vol. 4, No. 2

Beta-blocker therapy in heart failure: The new vascular biology imperative to blunt progression

This monograph, Beta-blocker therapy in heart failure: The new vascular biology imperative to blunt progression , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

Vascular Biology in Clinical Practice © Vol. 4, No. 1

LDL at the vascular wall: New insights, new relevance

This monograph, LDL at the vascular wall: New insights, new relevance , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

MERIT-HF: Benefits of ß-blockade in women with heart failure and reduced left ventricular function

Under-representation of women in heart failure (HF) clinical trials has created uncertainty about the efficacy of various treatment strategies in women.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Preventing stroke with ACE inhibition

Each year, approximately 750,000 Americans suffer a first or recurrent stroke.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section III: Neurohormonal strategies in heart failure

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section II: Lipid management

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section I: RAS manipulation

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Curriculum Update # 7

Managing renal disease for risk reduction: The expanding role of ACE inhibition

Chronic renal disease is a problem of increasing magnitude in the United States.

Vascular Biology in Clinical Practice © Vol. 3, No. 3

Lipids in the post-intervention continuum of care: New challenges and strategies in risk management

This monograph is offered as part of a series of educational programs published under the auspices of the VBWG, with continuing medical education credit provided by the University of Florida College of Medicine.

Curriculum Update # 6

Managing lipids for risk reduction: Focus on the new National Cholesterol Education Program guidelines

This Curriculum Update presents new perspectives on cholesterol management as suggested by the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III or ATP III).

Supplement to The American Journal of Cardiology October 18, 2001 vol. 88 (8A)

A Symposium: Interventions in cardiology: Focus on lipid management in acute and long-term settings

Exciting new data have emerged on the relative roles of medical therapy and percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS).

Vascular Biology in Clinical Practice © Vol. 3, No. 2

New insights into the antiatherosclerotic potential of ACE inhibition

This monograph, New insights into the antiatherosclerotic potential of ACE inhibition is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

Vascular Biology in Clinical Practice © Vol. 3, No. 1

Cardiovascular risk reduction in the diabetic patient

This monograph, Cardiovascular risk reduction in the diabetic patient , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

MIRACL: Very early statin therapy not guided by cholesterol levels is beneficial in acute coronary syndromes

Final results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial have been published and confirm that treatment with atorvastatin 80 mg/d early during an acute coronary syndrome (ACS) reduces the risk of early recurrent events, primarily recurrent symptomatic ischemia during hospitalization.

SECURE: ACE inhibition retards the progression of atherosclerosis

Final results of the Study to Evaluate Carotid Ultrasound changes with Ramipril and vitamin E (SECURE) have been published and confirm that treatment with ramipril 10 mg slows the progression of atherosclerosis, while treatment with vitamin E has no apparent effect.

Core Curriculum

Vascular biology for clinical practice: From basic concepts to mainstream medicine

Physicians who participated at recent Vascular Biology Working Group meetings have provided the direction for the development of these materials.

Curriculum Update #5

Interactions of lipids and RAS: Mechanisms for risk reduction

Hypertension and hypercholesterolemia, the major risk factors for atherosclerotic disease, are frequently associated.

Vascular Biology in Clinical Practice © Vol. 2, No. 3

Diabetes and cardiovascular disease: The emerging role of the endothelium and implications for treatment

This monograph Diabetes and cardiovascular disease: The emerging role of the endothelium and implications for treatment.

Lipids and RAS: Interactions that increase cardiovascular risk

Hypertension and hypercholesterolemia frequently coexist, and over the past decade, provocative data have emerged suggesting the existence of neurohormonal interactions between lipoproteins and the renin-angiotensin system (RAS).

Vascular Biology in Clinical Practice © Vol. 2, No. 2

RAS, lipids, and inflammation: New insights for therapeutic intervention

This monograph RAS, lipids, and inflammation: New insights for therapeutic intervention is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

Curriculum Update #4

Bradykinin and angiotensin-(1-7): Emerging allies in vascular function

The role of endothelial function in cardiovascular health provides an important conceptual framework for development of risk reduction strategies.

Vascular Biology in Clinical Practice © Vol. 2, No. 1

Bradykinin and angiotensin-(1-7): Emerging allies in vascular functioning

This monograph Bradykinin and Angiotensin-(1-7): Emerging allies in vascular functioning is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

Core Curriculum

The endothelium: New insights into the origins and treatment of CAD

Participants at recent Vascular Biology Working Group meetings have reviewed and provided significant direction in the development of this slide/lecture program entitled The endothelium: New insights into the origins and treatment of CAD.

Angiotensin-(1-7): New insights into the benefits of tissue ACE inhibition

Emerging new data are expanding our understanding of the renin-angiotensin system (RAS).

Postintervention Continuum of Care Update: Ultrasound Assessment of Plaque Dynamics

Lipids and plaque on ultrasound: New views and new dimensions

This slide lecture material is an update to the core curriculum entitled Postintervention Continuum of Care: Focus on Lipids

Angiotension type 1 receptor blockade versus ACE inhibition in the treatment of heart failure: Results of 3 clinical trials

Angiotension-converting enzyme (ACE) inhibitors are of critical importance for the treatment of patients with heart failure.

Curriculum Update #3

Clinical Trials Update: Tissue ACE inhibition offers new hope for treating cardiovascular disease

This Curriculum Update highlights important recent trials of tissue ACE inhibition in patients with cardiovascular disease and preserved left ventricular function.

Vascular Biology in Clinical Practice © Vol. 1, No. 4

Clinical trials update: Tissue ACE inhibition offers new hope for treating cardiovascular disease

Advances in vascular biology bring physicians the opportunity to apply new concepts in the treatment of patients with cardiovascular disease.

Data and Commentary: The BANFF Study

Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease

J Am Coll Cardiol.

Data and Commentary:The HOPE Study

Effects of angiotensin-converting enzyme inhibition on cardiovascular events in high-risk patients

The Heart Outcomes Prevention Evaluation Study Investigators.

Curriculum Update #2

From hypertension to LVH and heart failure

This new program focuses on an area in which our understanding of vascular biology may have had the most profound impact on clinical practice to date.

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.

Vascular Biology in Clinical Practice

The vascular endothelium and CAD: New target considerations in treating the cardiovascular dysmetabolic syndrome

This discourse is based on the proceedings of a national faculty meeting of the Vascular Biology Working Group held in Orlando earlier this year that explored the clustering of metabolic abnormalities associated with what previously has been recognized by many as "syndrome X.

Postintervention Continuum of Care: Focus on Lipids

This is the first in an educational initiative on the continuum of care essential to the well-being of postintervention patients, with a special focus on the importance of aggressive lipid management.

Vascular Biology in Clinical Practice © Vol. 1, No. 3

From hypertension to LVH and heart failure

Participants at recent Vascular Biology Working Group meetings have reviewed and provided significant direction in the development of this slide/lecture program entitled The endothelium: New insights into the origins and treatment of CAD.

The vascular endothelium and CAD: New target considerations in treating the cardiovascular dysmetabolic syndrome

The attached slide materials represent the seventh in a series of slide/lecture programs that focus on what continues to be one of the most exciting new fields of emerging data: The endothelium and its role in cardiovascular health and disease.

Curriculum Update #1

Overview of clinical trials to improve endothelial function

The contents of the curriculum update represent a concise overview of clinical trials in the emerging field of study relating to the endothelium and its role in cardiovascular health and disease.

Vascular Biology in Clinical Practice © Vol. 1, No. 2

Overview of clinical trials to improve endothelial function

Fundamental views on the progression of cardiovascular disease are evolving toward a clearer understanding that the endothelium plays a central role in health and disease.

New data on the anti-ischemic effects of ACE inhibition

During the past decade, results from a number of clinical trials have revolutionized the way clinicians treat CHD and CAD.

Vascular Biology in Clinical Practice © Vol. 1, No. 1

The endothelium: Redefining the origins of cardiovascular disease

This CME monograph is the first in a series of educational programs aimed at taking the mystery out of vascular biology and making it relevant to patient care.

Core Curriculum

Endothelial function: Changing the pattern of treating CV disease

The attached slide materials represent the fifth in a series of slide/lecture programs that focus on what continues to be one of the most exciting new fields of emerging data: The endothelium and its role in cardiovascular health and disease.

Focus: Lipids and the Endothelium

The Endothelium: Impact on CAD treatment strategies

These slide materials represent the third in a series of slide/lecture programs that focus on what continues to be one of the most exciting new fields of emerging data: The endothelium and its role in cardiovascular health and disease.